ZD 2767

Subscribe to Selected New Research on ZD 2767

4 relevant articles (1 outcomes, 1 trials/studies) found for this Bio-Agent

Description: a candidate prodrug for antibody-directed enzyme prodrug therapy; structure given in first source

Also Known As:

(((4-(bis(2-iodoethyl)amino)phenyl)oxy)carbonyl)glutamic acid; ZD-2767; ZD2767; ZD2767P

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Halogenated Hydrocarbons: 28

Mustard Compounds: 3

Nitrogen Mustard Compounds: 1

ZD 2767: 4

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 07/15/1996 - "These studies demonstrate the potential of ZD2767 for the treatment of colorectal cancer." 07/15/1996 - "ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts." Get all the results and reference details, order at left...
2.	Neoplasms (Cancer) 05/15/2007 - "Following delivery of the vector (AdV.hTERT-CPG2) and expression of CPG2 in cancer cells, the prodrug ZD2767P was administered for conversion by CPG2 to a cytotoxic drug" 07/15/1996 - "Administration of the ZD2767 conjugate to nude mice bearing LoVo colorectal xenografts resulted in approximately 1% of injected ZD2767 conjugate localizing/g of tumor after 72 h, and blood and normal tissue levels of the conjugate were 10-50-fold lower" 07/15/1996 - "ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts." Get all the results and reference details, order at left...
3.	Small Cell Carcinoma (Small Cell Lung Cancer) 07/01/2002 - "The prodrug 4-[N,N-bis(2-iodoethyl)amino]phenoxycarbonyl L-glutamic acid (ZD2767P)+activating enzyme carboxypeptidase G2 (CPG2) displayed growth inhibitory activity (IC(50) 0.04-2.2 microM) in colorectal tumour and non-small cell lung cancer (NSCLC) cell lines, and was more potent than a monofunctional ZD2767D analogue (colorectal cell lines-IC(50) 18-38 microM), synthesized for the first time" Get all the results and reference details, order at left...
4.	Carcinoma (Carcinomatosis) 01/15/2005 - "Biodistribution and therapeutic effect of a single ADEPT cycle (1,000 units/kg MFE-CP followed by 70 mg/kg ZD2767P prodrug at 6, 7, and 8 hours) and multiple ADEPT cycles (9-10 cycles within 21-24 days) was studied in established human colon carcinoma xenografts, LS174T, and SW1222" Get all the results and reference details, order at left...
4 Diseases and 4 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Glutamic Acid (Glutamate)
2.	gamma-Glutamyl Hydrolase (Carboxypeptidase G2)
3.	icodextrin (Extraneal)
3 Drugs and Important Bio-Agents and 2 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
1 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>